ProPhase Labs (NASDAQ:PRPH) Stock Crosses Below 200 Day Moving Average – What’s Next?

ProPhase Labs, Inc. (NASDAQ:PRPH)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.42 and traded as low as $0.1402. ProPhase Labs shares last traded at $0.1503, with a volume of 146,678 shares changing hands.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded ProPhase Labs to a “hold” rating in a research report on Saturday, December 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, ProPhase Labs has a consensus rating of “Sell”.

ProPhase Labs Price Performance

The company has a market capitalization of $905,106.60, a price-to-earnings ratio of -0.04 and a beta of -0.33. The company has a quick ratio of 0.14, a current ratio of 0.14 and a debt-to-equity ratio of 0.14. The company has a 50 day simple moving average of $0.13 and a 200 day simple moving average of $1.42.

Institutional Investors Weigh In On ProPhase Labs

Several institutional investors and hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP boosted its position in shares of ProPhase Labs by 290.1% in the third quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock worth $182,000 after buying an additional 295,899 shares during the period. Accretive Wealth Partners LLC purchased a new stake in shares of ProPhase Labs in the third quarter worth about $114,000. Apollon Wealth Management LLC purchased a new stake in shares of ProPhase Labs in the third quarter worth about $84,000. Finally, XTX Topco Ltd purchased a new stake in shares of ProPhase Labs in the second quarter worth about $40,000. Hedge funds and other institutional investors own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.